Literature DB >> 20811330

Tenofovir nephrotoxicity: acute tubular necrosis with distinctive clinical, pathological, and mitochondrial abnormalities.

Leal C Herlitz1, Sumit Mohan, Michael B Stokes, Jai Radhakrishnan, Vivette D D'Agati, Glen S Markowitz.   

Abstract

Tenofovir, a widely prescribed antiretroviral medication for treatment of HIV-1 infection, is infrequently associated with renal dysfunction and biopsy findings of acute tubular necrosis. We examined the clinical and pathological findings in 13 cases of tenofovir nephrotoxicity (7 men and 6 women, mean age of 51.1±9.6 years). Patients received tenofovir therapy for a mean of 19.6 months (range, 3 weeks to 8 years; median 8 months). Nine patients presented with acute kidney injury, and four had mild renal insufficiency with subnephrotic proteinuria. Mean baseline serum creatinine was 1.3±0.3 mg/dl, reaching 5.7±4.0 mg/dl at the time of biopsy, with mean proteinuria of 1.6±0.3 g/day. Glycosuria was documented in seven patients, five of whom were normoglycemic. Renal biopsy revealed toxic acute tubular necrosis, with distinctive proximal tubular eosinophilic inclusions representing giant mitochondria visible by light microscopy. Electron microscopy showed mitochondrial enlargement, depletion, and dysmorphic changes. Clinical follow-up after tenofovir discontinuation was available for 11 of 13 patients (mean duration 13.6 months). Significant recovery of renal function occurred in all patients, including four who required transient hemodialysis. Our study shows that tenofovir nephrotoxicity is a largely reversible form of toxic acute tubular necrosis targeting proximal tubules and manifesting distinctive light microscopic and ultrastructural features of mitochondrial injury.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20811330     DOI: 10.1038/ki.2010.318

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  98 in total

1.  HIV and mitochondria: more than just drug toxicity.

Authors:  Todd Hulgan; Mariana Gerschenson
Journal:  J Infect Dis       Date:  2012-04-03       Impact factor: 5.226

2.  In Vitro and In Vivo Evidence on the Role of Mitochondrial Impairment as a Mechanism of Lithium-Induced Nephrotoxicity.

Authors:  Mohammad Mehdi Ommati; Hossein Niknahad; Omid Farshad; Negar Azarpira; Reza Heidari
Journal:  Biol Trace Elem Res       Date:  2020-07-25       Impact factor: 3.738

3.  Short Communication: Resolution of Tenofovir Disoproxil Fumarate Induced Fanconi Syndrome with Switch to Tenofovir Alafenamide Fumarate in a HIV-1 and Hepatitis B Coinfected Patient.

Authors:  Maile Young Karris
Journal:  AIDS Res Hum Retroviruses       Date:  2017-05-12       Impact factor: 2.205

4.  Design, Synthesis, and Anti-HBV Activity of New Bis(l-amino acid) Ester Tenofovir Prodrugs.

Authors:  Apeng Wang; Shuo Wu; Zeyu Tao; Xiaoning Li; Kai Lv; Chao Ma; Yuhuan Li; Linhu Li; Mingliang Liu
Journal:  ACS Med Chem Lett       Date:  2019-05-16       Impact factor: 4.345

5.  Association of tenofovir exposure with kidney disease risk in HIV infection.

Authors:  Rebecca Scherzer; Michelle Estrella; Yongmei Li; Andy I Choi; Steven G Deeks; Carl Grunfeld; Michael G Shlipak
Journal:  AIDS       Date:  2012-04-24       Impact factor: 4.177

6.  Reversibility of Glomerular Renal Function Decline in HIV-Uninfected Men and Women Discontinuing Emtricitabine-Tenofovir Disoproxil Fumarate Pre-Exposure Prophylaxis.

Authors:  Kenneth K Mugwanya; Christina Wyatt; Connie Celum; Deborah Donnell; James Kiarie; Allan Ronald; Jared M Baeten
Journal:  J Acquir Immune Defic Syndr       Date:  2016-04-01       Impact factor: 3.731

7.  Longitudinal Assessment of Proximal Tubular Dysfunction in HIV Seropositive and Seronegative Persons: Correlates and Implications.

Authors:  Kerry M Sheets; Mohamed G Atta; Derek M Fine; Katie Zook; Allison M Mcfall; Michelle M Estrella; George J Schwartz; Gregory M Lucas
Journal:  J Acquir Immune Defic Syndr       Date:  2017-05-01       Impact factor: 3.731

8.  Kidney disease in the setting of HIV infection: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference.

Authors:  Charles R Swanepoel; Mohamed G Atta; Vivette D D'Agati; Michelle M Estrella; Agnes B Fogo; Saraladevi Naicker; Frank A Post; Nicola Wearne; Cheryl A Winkler; Michael Cheung; David C Wheeler; Wolfgang C Winkelmayer; Christina M Wyatt
Journal:  Kidney Int       Date:  2018-02-03       Impact factor: 10.612

9.  The Use of Cytochrome C Oxidase Enzyme Activity and Immunohistochemistry in Defining Mitochondrial Injury in Kidney Disease.

Authors:  Zsuzsanna K Zsengellér; Seymour Rosen
Journal:  J Histochem Cytochem       Date:  2016-09       Impact factor: 2.479

10.  Tenofovir treatment duration predicts proteinuria in a multiethnic United States Cohort of children and adolescents with perinatal HIV-1 infection.

Authors:  Murli Purswani; Kunjal Patel; Jeffrey B Kopp; George R Seage; Miriam C Chernoff; Rohan Hazra; George K Siberry; Lynne M Mofenson; Gwendolyn B Scott; Russell B Van Dyke
Journal:  Pediatr Infect Dis J       Date:  2013-05       Impact factor: 2.129

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.